<DOC>
	<DOCNO>NCT01319773</DOCNO>
	<brief_summary>This study evaluate safety , tolerability pharmacokinetics two formulation cyclosporine ophthalmic emulsion healthy adult ( parallel-group phase ) . The parallel-group phase follow paired-eye phase evaluate safety tolerability two formulation cyclosporine ophthalmic emulsion compare cyclosporine ophthalmic emulsion ( RESTASIS® ) patient dry eye .</brief_summary>
	<brief_title>Study Two Formulations Cyclosporine Ophthalmic Emulsion Healthy Volunteers Patients With Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>ParallelGroup Phase : Weigh least 110 lbs 18 45 year old PairedEye Phase : Dry eye disease eye ParallelGroup Phase : Use nicotine product , medication , supplement herbal product consumption grapefruit juice within 14 day anticipate use study Has donate blood within 90 day Significant weight change ( 10 lb ) within 60 day Previous use RESTASIS® ParallelGroup PairedEye Phases : Anticipated wear contact lens study wear contact lens within 14 day Consumption alcohol product within 72 hour PairedEye Phase : Previous ocular surgery Use RESTASIS® within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>